Welcome to our dedicated page for HilleVax news (Ticker: HLVX), a resource for investors and traders seeking the latest updates and insights on HilleVax stock.
HilleVax, Inc. (HLVX) has been described in its public communications as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with an emphasis on virus-like particle (VLP) based vaccine candidates targeting norovirus-related acute gastroenteritis. The HLVX news feed on Stock Titan brings together company-issued press releases and SEC-referenced disclosures that trace both its clinical progress and its corporate transformation.
Readers can review announcements covering clinical trial milestones for HIL-214 and HIL-216, including topline data from the NEST-IN1 Phase 2b study in infants, the decision to discontinue further development of HIL-214 in infants, and statements about exploring potential continued development of norovirus vaccine candidates in adults. The news record also includes updates on financial results, such as quarterly and full-year reports that discuss research and development expenses, general and administrative costs, and the company’s cash, cash equivalents and marketable securities.
Another key theme in HilleVax’s news flow is strategic and corporate actions. In 2024, the company announced a workforce reduction intended to reduce operating expenses while maintaining core capabilities. In 2025, HilleVax disclosed that it was exploring strategic alternatives and later announced a definitive merger agreement under which XOMA Royalty Corporation would acquire all outstanding HilleVax shares for cash plus a contingent value right. Subsequent news and related SEC filings describe the tender offer, completion of the merger, and HilleVax’s transition to a wholly owned subsidiary of XOMA Royalty.
For investors and researchers, the HLVX news page serves as an archive of historical company developments, from clinical-stage vaccine work to the finalization of its acquisition and delisting from Nasdaq. Users interested in the evolution of HilleVax’s norovirus vaccine programs, its financial reporting history, and the structure of its merger with XOMA Royalty can use this page to follow the sequence of publicly reported events.
Summary not available.
Summary not available.
Summary not available.
HilleVax, Inc. (Nasdaq: HLVX) announced the completion of enrollment for its NEST-IN1 trial, a Phase 2b study evaluating HIL-214, a vaccine candidate for norovirus, with over 3,000 subjects enrolled across six countries. The trial focuses on infants aged around 5 months and aims to assess the vaccine's efficacy and safety against moderate-to-severe norovirus-related acute gastroenteritis (AGE). Topline safety and clinical efficacy data are anticipated in Q1 2024. Currently, there are no approved vaccines for norovirus, which causes approximately 700 million cases of AGE and 200,000 deaths annually, highlighting the critical need for effective vaccination.
HilleVax, Inc. (Nasdaq: HLVX) reported its financial results for 2022, highlighting key achievements and future milestones. The company ended 2022 with cash reserves of $279.4 million and experienced significant increases in both research and development expenses, totaling $45.9 million, compared to $10.0 million in 2021. For Q4 2022, the net loss reached $21.2 million, up from $37.3 million in Q4 2021, while the full year net loss was $159.8 million, compared to $102.4 million in the prior year. Upcoming milestones include topline data from the Phase 2b NEST-IN1 clinical trial expected in Q1 2024.
HilleVax, a clinical-stage biopharmaceutical company, announced key leadership changes including Ozzie Berger as Senior VP of Regulatory Affairs, Anju Chatterji as Chief Technical Officer, and Shane Maltbie as Chief Financial Officer. These promotions are part of a strategic transition aimed at enhancing their Phase 2b trial of HIL-214, a vaccine for norovirus. Berger brings nearly 30 years of experience, while Chatterji and Maltbie have significant backgrounds in technical operations and financial management, respectively. The company emphasizes the ongoing enrollment and expected data readouts from its clinical trials.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The presentation will cover HIL-214, an investigational vaccine for moderate-to-severe norovirus-related acute gastroenteritis, and the ongoing Phase 2b study NEST-IN1. The event will be held at the Westin St. Francis Hotel in San Francisco, starting at 4:30 p.m. EST. HilleVax aims to address the significant health burden of norovirus, which affects millions globally.
HilleVax reported results from the NEST-IN1 trial, focusing on the immunogenicity of its vaccine candidate HIL-214 for norovirus prevention in infants. In the trial's run-in cohort of 203 subjects, geometric mean titers (GMTs) of pan-IG antibodies were significantly higher for HIL-214 compared to placebo, with a greater than 18-fold increase observed. The seroresponse rates were 99.0% for GI.1 and 86.9% for GII.4 in the HIL-214 group versus only 4.1% and 3.1% for placebo. The full trial aims to enroll 3,000 subjects, with topline safety and efficacy data expected in late 2023.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. Key discussions will focus on HIL-214, an investigational virus-like particle vaccine aimed at preventing moderate-to-severe norovirus-related gastroenteritis, and its ongoing Phase 2b clinical trial, NEST-IN1. Events are scheduled for November 14 and November 16, 2022, featuring CEO Robert Hershberg.
HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company, reported third-quarter financial results for 2022, highlighting progress on its investigational vaccine HIL-214 for norovirus. The company began enrollment for 2,800 subjects in the Phase 2b NEST-IN1 trial and expects immunogenicity results from the initial 200 subjects in Q4 2022. HilleVax reported a cash balance of $292.1 million and a net loss of $16.8 million for the quarter, a significant reduction from $61.9 million in Q3 2021. R&D expenses were $13.3 million, up from $0.9 million the previous year.